¶µ¼ø ÆîÂô¡¡µý¶µ¼ø¼Ì¿¿
¹Ö»Õ

ÊëÃÏËÜ¡¡Ãè¸Ê
ëü¡¡½ß

Âç³Ø±¡À¸

Âíß·¡¡Îç±û

µÒ°÷¶µ¼ø

ÀÐÀî¡¡µÁ¹°

 
¹ÖºÂ¡Ê¸¦µæ¼¼¡Ë¤Î³µÍ×
¡¡±§Ãè¹Ò¶õ°å³Ø¸¦µæ¼¼¤Ï¾¼ÏÂ40ǯ4·î¤Ë±§Ãè°å³Ø¸¦µæ¼¼¤È¤·¤Æ³«Àߤµ¤ì¤Þ¤·¤¿¡£½éÂ嶵¼ø¤Ïº´Çì镹¶µ¼ø¤Ç¤½¤Î¸å¡¢°æÀͺ¶µ¼ø¡¢ËÜÅÄ˧Ã˶µ¼ø¡¢¼ò°æµª¶µ¼ø¡¢·ª¸¶ÉÒ¶µ¼ø¤È°ú¤­·Ñ¤¬¤ì¤Þ¤·¤¿¡£Ê¿À®7ǯ6·î¤ËÁÈ¿¥Âؤ¨¤Î¤¿¤áºÙ˦À¸Íý³Ø¹ÖºÂ¡ÊÅö»þÀ¸Íý³Ø¹ÖºÂÂ裲¡Ë¤Î»±²¼¤È¤Ê¤ê¡¢Ì¾¾Î¤â±§Ãè¹Ò¶õ°å³Ø¸¦µæ¼¼¤È²þ̾¤·¡¢±§Ãè¹Ò¶õ°å³Ø¤ª¤è¤Ó´Ä¶­°å³Ø¤Î¸¦µæ¤È¶µ°é¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£
°å³Ø²Ê¶µ°é¤Ë¤Ä¤¤¤Æ
¡¡1ǯÀ¸¤Ë¤Ï¡¢¶µÍÜ¥¼¥ß¡Ö±§Ãè°å²Ê³ØÆþÌç¡×¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£2ǯÀ¸Á°´ü¤Ë¤ÏºÙ˦¤«¤é¸ÄÂΤؼ½¬¤Î¤Ê¤«¤ÎÁÈ¿¥³ØÁíÏÀ¤Ë·È¤ï¤Ã¤Æ¤¤¤Þ¤¹¡£2ǯÀ¸¸å´ü¤Ë¤Ïµ¡Ç½·Ï¼Â½¬¡ÊÀ¸Íý³Ø·Ï¡Ë¤Ç¿´ÅÅ¿Þ¡¢¸ÆµÛ¼Â½¬¤Ê¤É¤ò¹Ô¤Ê¤¤¡¢¤Þ¤¿·ÁÂַϼ½¬¡ÊÁÈ¿¥¡Ë¤Ë¤â·È¤ï¤Ã¤Æ¤¤¤Þ¤¹¡£3ǯÀ¸¤Ë¤Ï¾É¸õ³Ø±é½¬¤Ë¤ª¤¤¤Æ¥Á¥å¡¼¥¿¡¼¤ò̳¤á¤Æ¤¤¤Þ¤¹¡£¸¦µæ¼¼ÇÛ°¤Ç¤Ï¡¢±§Ãè°å³Ø¡¢¹Ò¶õ°å³Ø¡¢´Ä¶­°å³Ø¤Ê¤É¤Ë´Ø¤¹¤ë¸¦µæ¤ò³ØÀ¸¤¬¼çÂΤȤʤäƹԤʤäƤ¤¤Þ¤¹¡£5ǯÀ¸¤Î²ÊÌܤǤϡ¢Í½ËÉ°å³Ø¤Ë·È¤ï¤Ã¤Æ¤¤¤Þ¤¹¡£
°å³Ø²Ê¶µ°é¤Ë¤Ä¤¤¤Æ
¡¡±§Ãè¹Ò¶õ°å³Ø¸¦µæ¼¼¤Ç¤Ï¡¢±§Ãè°å³Ø¡¦±§ÃèÀ¸Ì¿²Ê³Ø¤Î¸¦µæ¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤Þ¤¹¡£ºÙ˦¥ì¥Ù¥ë¤Ç¤Ï¡¢¸¦µæ¼¼¤ËÀßÃÖ¤µ¤ì¤Æ¤¤¤ë½ÅÎÏÀ©¸æÁõÃÖ¡ÖGravite¡×¤òÍѤ¤¤Æ¡¢¿´·ì´É·Ï¤ä¹ü³Ê¶Ú·Ï¤Ê¤É¤ËͳÍ褹¤ëºÙ˦¤Ø¤Î½ÅÎÏÊѲ½¤Î±Æ¶Á¤ò²òÌÀ¤¹¤ë¸¦µæ¤ò¼Â»Ü¤·¤Æ¤¤¤Þ¤¹¡£¤Þ¤¿¸ÄÂÎ¥ì¥Ù¥ë¤Ç¤Ï¡¢±§Ãè¹Ò¶õ¸¦µæ³«È¯µ¡¹½ ¡ÊJAXA¡Ë¤È¶¦Æ±¸¦µæ·ÀÌó¤òÄù·ë¤·¡¢¹ñºÝ±§Ã襹¥Æ¡¼¥·¥ç¥ó¤ËÂںߤ·¤¿¥Þ¥¦¥¹¤ËÀ¸¤¸¤ëÀ¸ÍýÊѲ½¤òÌÀ¤é¤«¤Ë¤¹¤ë¸¦µæ¤ò¿ä¿Ê¤·¤Æ¤¤¤Þ¤¹¡£Ëܸ¦µæ¼¼¤Ç¤Ï¡¢¥ª¥ß¥Ã¥¯¥¹²òÀϤäʬ»ÒºÙ˦À¸Êª³ØŪ¼êË¡¤Ë²Ã¤¨¤Æ¡¢¸÷¸²¡¦Æ©²áÅŸ²¡¦ÁöººÅŸ²¤òÍѤ¤¤¿Â¿ÍͤʷÁÂÖ³ØŪ²òÀϼêË¡¤ò³èÍѤ·¡¢µ¡Ç½¤È·ÁÂÖ¤ÎξÎؤǡ¢À¸Ì¿¤Î±§ÃèŬ±þ¤ÎÍý²ò¤òÌܻؤ·¤Æ¤¤¤Þ¤¹¡£¿ÍÎà¤Î±§Ãè¿Ê½Ð¤Ëȼ¤¤À¸¤¸¤ë¤Èͽ¸«¤µ¤ì¤ë·ò¹¯ÌäÂê¤ò²ò·è¤·¡¢¸¦µæÀ®²Ì¤òÃϾå¼Ò²ñ¤Ë´Ô¸µ¤·¤Æ¤¤¤¯¤¿¤á¡¢Í½ËÉ°å³Ø¤Î´ÑÅÀ¤â¼è¤êÆþ¤ì¤Æ¸¦µæ¤òŸ³«¤·¤Æ¤¤¤Þ¤¹¡£
¹ÖºÂ(¸¦µæ¼¼)¤«¤é¤Î¥á¥Ã¥»¡¼¥¸
¡¡¡Ö±§Ãè¡×¤Ïº£¡¢¿ÍÎàºÇ¸å¤Î¥Õ¥í¥ó¥Æ¥£¥¢¤Ç¤¹¡£¤³¤Î̤ƧÎΰè¤Ë¤Ï¡¢À¸Ì¿¤ÎÆæ¤È²ÝÂ꤬¤Þ¤À¿¤¯»Ä¤µ¤ì¤Æ¤¤¤Þ¤¹¡£Ëܸ¦µæ¼¼¤Ç¤Ï¡¢°ÕÍßŪ¤Ë±§Ãè°å³Ø¡¦±§ÃèÀ¸Ì¿²Ê³Ø¤Ë¼è¤êÁȤߤ¿¤¤Âç³Ø±¡´õ˾¼Ô¤Ê¤É¤ò´¿·Þ¤¤¤¿¤·¤Þ¤¹¡£±§Ã褬¥Õ¥í¥ó¥Æ¥£¥¢¤Ç¤Ê¤¯¤Ê¤ëÆü¤Ï¡¢¤¢¤Ê¤¿¤Ë¤è¤Ã¤ÆÅþÍ褹¤ë¤«¤â¤·¤ì¤Þ¤»¤ó¡£¤Ê¤ª¡¢±§Ãè¹Ò¶õ°å³Ø¤Ë¶½Ì£¤ò¤ª»ý¤Á¤Î¸¦µæ¼Ô¡¦Ã´Åö¼Ô¤ÎÊý¤Î¤ªÌ䤤¹ç¤ï¤»¤â¤ªÂÔ¤Á¤·¤Æ¤ª¤ê¤Þ¤¹¡£¤ªµ¤·Ú¤Ë¤´ÁêÃ̤¯¤À¤µ¤¤¡£
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¶µ°éôÅö
¼Â½¬²ÊÌÜ̾¾Î¤ÈÂоݳØǯ

£±Ç¯À¸¡§¶µÍÜ¥¼¥ß
£²Ç¯À¸¡§µ¡Ç½·Ï¼Â½¬¡ÊÀ¸Íý¡Ë¡¢ºÙ˦¤«¤é¸ÄÂΤؼ½¬¡¢·ÁÂַϼ½¬¡ÊÁÈ¿¥¡Ë¡¢·ÁÂַϼ½¬¡Ê¿À·Ð¡Ë¡¢ÈçÇ¢´ï·Ï¹ÖµÁ¡¢ÆâʬÈç·Ï¹ÖµÁ
£³Ç¯À¸¡§¾É¸õÉÂÂּ½¬­¶¡Ê¥â¥Ç¥å¥ì¡¼¥¿¡¼¡¢¥Ç¥å¥ì¡¼¥¿¡¼¡Ë¡¢¸¦µæ¼¼ÇÛ°¡¢´¶À÷¡¦Ìȱ֥ƥ塼¥È¥ê¥¢¥ë¡¢°å³Ø±Ñ¸ìÀìÌçʸ¸¥¾¶ÆÉ­µ
£´Ç¯À¸¡§¾É¸õ¤«¤éÉÂÂÖ¤Ø
£µÇ¯À¸¡§Í½ËÉ°å³Ø

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
Âç³Ø±¡Ã´Åö²ÊÌÜ̾¾Î
Âç³Ø±¡¥¬¥¤¥É¼ø¶ÈºÙÌÜ¡¡½Û´ÄÀ¸Íý³Ø¡Ê16¥Ú¡¼¥¸¡Ë¤ò¤´»²¾È¤¯¤À¤µ¤¤
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¸¦µæ¥Æ¡¼¥Þ
¼Â¸³¸¦µæ
¹ü³Ê¶Ú°à½Ì¤Ø¤ÎCa2+¥·¥°¥Ê¥ë¤Î´ØÍ¿¤Ë´Ø¤¹¤ë¸¦µæ
¶Ú°à½Ì¤ÎÉÂÂÖ¤ËÇ÷¤ë¥ß¥È¥³¥ó¥É¥ê¥¢¤ÎÌò³ä²òÌÀ¤Ë´Ø¤¹¤ë¸¦µæ

¶Ú¤Î²ÄÁºÀ­¤ËÂФ¹¤ë¥Ó¥¿¥ß¥ó£Ä¤Î¸ú²Ì¤Ë´Ø¤¹¤ë¸¦µæ

±§ÃèÂںߥޥ¦¥¹¤Î³ÆÁÈ¿¥¤Ø¤ÎÈù¾®½ÅÎϴĶ­¤Î±Æ¶Á¤ËÂФ¹¤ë·ÁÂÖ³ØŪ²òÀÏ
¡Ê2018¡¦2019¡¦2020ǯÅÙ¡Ö¤­¤Ü¤¦¡×ÍøÍÑ¥Þ¥¦¥¹¥µ¥ó¥×¥ë¥·¥§¥¢¥Æ¡¼¥ÞºÎÂò²ÝÂê¡Ë
½ÅÎÏÀ©¸æÁõÃÖGravite¤òÍѤ¤¤¿ºÙ˦¤Îµ¡Ç½·ÁÂ֤ؤνÅÎϤαƶÁ¤Î²òÀÏ
¶Ë¸Â¾õ¶·²¼¤Ë¤ª¤±¤ë¡´ïÊݸ¼£ÎÅË¡¤Î¸¦µæ
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶ÈÀÓ
¡Ú¸¶ÃøÏÀʸ¡Ê2020ǯ°Ê¹ß¡Ë¡Û
  1. Bochimoto H, Kondoh D, Ishihara Y, Mohammad Hazzaz Bin Kabir, and Kentaro Kato. Functional perspective of feeder organelle from three-dimensional ultrastructural characteristics in cryptosporidium parvum. Journal of Integrated Field Science 17:1-4, 2020.
  2. Ishihara Y, Bochimoto H, Kondoh D, Obara H, Matsuno N. The ultrastructural characteristics of bile canaliculus in porcine liver donated after cardiac death and machine perfusion preservation. PloS One 15:e0233917, 2020.
  3. Matsuzaka Y, Tanihata J, Ooshima Y, Yamada D, Sekiguchi M, Miyatake S, Aoki Y, Terumitsu M, Yashiro R, Komaki H, Ishiyama A, Oya Y, Inoue YU, Inoue T, Takeda S, Hashido K. The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice. BMC Med 18:343, 2020.
  4. Yamada Y, Kusakari Y, Akaoka M, Watanabe M, Tanihata J, Nishioka N, Bochimoto H, Akaike T, Tachibana T, Minamisawa S. Thiamine treatment preserves cardiac function against ischemia injury via maintaining mitochondrial size and ATP levels. J Appl Physiol (1985) 130:26-35, 2020.
  5. Senoo N, Miyoshi N, Kobayashi E, Morita A, Tanihata J, Takeda S, Miura S. Glycerophospholipid profile alterations are associated with murine muscle-wasting phenotype. Muscle Nerve 62:413-8, 2020.
  6. Tanihata J, Fujii T, Baba S, Fujimoto Y, Morimoto S, Minamisawa S. Troponin T amino acid mutation (¦¤210) knock-in mice as a neonatal dilated cardiomyopathy model. Pediatr Res 89:846-857, 2020.
  7. Bochimoto H, Ishihara Y, Mohd Zin NK, Iwata H, Kondoh D, Obara H, Matsuno N. Ultrastructural changes in porcine liver sinusoidal endothelial cells of machine perfused liver donated after cardiac death. World J Gastroenterol 28: 2100-11, 2022.
  8. Ito A, Hashimoto M, Tanihata J, Matsubayashi S, Sasaki R, Fujimoto S, Kawamoto H, Hosaka Y, Ichikawa A, Kadota T, Fujita Y, Takekoshi D, Ito S, Minagawa S, Numata T, Hara H, Matsuoka T, Udaka J, Araya J, Saito M, Kuwano K. Involvement of Parkin-mediated mitophagy in the pathogenesis of chronic obstructive pulmonary disease-related sarcopenia. J Cachexia Sarcopenia Muscle 13: 1864-1882, 2022.
  9. Bin Kabir MH, Recuenco FC, Mohd Zin NK, Watanabe N, Fukuda Y, Bando H, Watanabe K, Bochimoto H, Xuan X, Kato K. Identification of potent anti-Cryptosporidium new drug leads by screening traditional Chinese medicines. PLoS Negl Trop Dis 16: e0010947, 2022.
¡ÚÁíÀâ(2020ǯ°Ê¹ß)¡Û
  1. ÊëÃÏËÜÃè¸Ê¡§´¶À÷Ëɸæ¤Î¤¿¤á¤Î±§ÃèÀ¸Ì¿²Ê³Ø¸¦µæ : ¼¡À¤Âå¤ÎÍ­¿Í±§ÃèÈô¹Ô¤Ë¸þ¤±¤Æ (Æý¸ ±§ÃèÀ¸Ì¿²Ê³Ø¤Î¿ÊÊâ¤È°å³Ø±þÍѤؤΟ˾). °å³Ø¤Î¤¢¤æ¤ß 279; 583-588, 2021.
  2. ÊëÃÏËÜÃè¸Ê. ¤Þ¤¹¤Þ¤¹³èÌö¤¹¤ë»º¶ÈÊÝ·ò´Ç¸î¿¦¤Ø ¡§ ¾­Íè¤Î±§Ãè»þÂå¤Þ¤Ç¸«¿ø¤¨¤Æ.»º¶ÈÊÝ·ò¤È´Ç¸î 14: 25-29, 2022.
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¼ç¤Ê¶¥ÁèŪ¸¦µæÈñ
¡Ú2020ǯÅÙ¡Û
    Âåɽ¸¦µæ¼Ô
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(C) Âåɽ¸¦µæ¼Ô¡ÊÊëÃÏËÜ¡Ë
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(C) Âåɽ¸¦µæ¼Ô¡Êëü¡Ë
  • ʬô¸¦µæ¼Ô
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(A) ʬô¸¦µæ¼Ô¡Êëü¡Ë
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(B) ʬô¸¦µæ¼Ô¡ÊÊëÃÏËÜ¡Ë
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(C) ʬô¸¦µæ¼Ô¡ÊÊëÃÏËÜ¡Ë
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(C) ʬô¸¦µæ¼Ô¡Êëü¡Ë
  • ʸÉô²Ê³Ø¾Ê²Ê³Ø¸¦µæÈñ½õÀ®»ö¶È¡¦´ðÈ׸¦µæ(C) ʬô¸¦µæ¼Ô¡Êëü¡Ë
¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø
¤½¤Î¾

¼õ¾Þ¡¡Ã«Ã¼¡¡½ß¡¥Âè11²óÆþß·¹¨¡¦ºÌµ­Ç°¼ã¼ê¸¦µæ¾©Îå¾Þ¡Ê¿´Â¡¡¦½Û´ÄÉôÌç¡Ë¡¥ÆüËÜÀ¸Íý³Ø²ñ¡¡2020ǯ3·î

¼õ¾Þ¡¡¸¶¸ý¡¡¹â¿­. Âè68²óÆüËܱ§Ãè¹Ò¶õ´Ä¶­°å³Ø²ñÂç²ñ. ºÇÍ¥½¨³ØÀ¸ÏȾÞ, 2022ǯ


¤½¤Î¾¤Î¼Ò²ñ³èÆ°

°°Àî°å²ÊÂç³ØµÒ°÷½Ú¶µ¼ø¡¡¡ÊÊëÃÏËÜ¡Ë

ÂÓ¹­ÃÜ»ºÂç³Ø¸¶Ãîɸ¦µæ¥»¥ó¥¿¡¼¶¦Æ±¸¦µæ°÷¡¡¡ÊÊëÃÏËÜ¡Ë

ÆüËܱ§Ãè¹Ò¶õ´Ä¶­°å³Ø²ñ¡¡É¾µÄ°÷¡¢ÊÔ½¸°Ñ°÷¡¢´ë²è°Ñ°÷¡¢±§Ãè´ðÃÏ°å³Ø¸¦µæ²ñÀ¤Ïÿ͡¢±§Ãè¹Ò¶õ´Ä¶­°å³Ø¼ã¼ê¤Î²ñÀ¤Ïÿ͡ÊÊëÃÏËÜ¡Ë

ÆüËÜÂÎÎÏ°å³Ø²ñ¡¡É¾µÄ°÷¡Êëü¡Ë

ÆüËÜÀ¸Íý³Ø²ñ¡¡É¾µÄ°÷¡Êëü¡Ë

¢¥ ¤³¤Î¥Ú¡¼¥¸¤Î¥È¥Ã¥×¤Ø